CADTH Releases Pharmaceutical Review Update Issue 4

Home CADTH Releases Pharmaceutical Review Update Issue 4

New updates from pCODR are as follows:

  1. Webinar on Clinician Input and Feedback Seminar
    CADTH is hosting a webinar in collaboration with Innovation Medicines Canada (IMC) on January 22nd, 12:00 pm to 1:00 pm EST, to provide detailed information about this process and new tools being offered for clinicians. This webinar is open to everyone and will be of particular interest to all who are involved in pCODR submissions and clinician engagement. To log into the webinar: https://innovativemeds.adobeconnect.com/pcodr_clinician_input_webinar/.For toll-free audio: 1-877-394-5901; Access code: 7568417
  2. Pre-Submission Information Requirement FormsCADTH is reminding submitters to complete, to the greatest extent possible, the Pre-Submission Information Requirement Forms – Submissions. Completing this form allows for pCODR’s resource planning and alerts the Provincial Advisory Group (PAG) of a pending review. The pre-submission information is also used to inform the new template for clinician input (refer to webinar described above on January 22, 2019)
  3. Upcoming 2019 Oncology Drugs in Pipeline SurveypCODR is targeting their latest Oncology Drugs in Pipeline Survey to be sent to participating pharmaceutical manufacturers in February 2019.  This survey allows participating pharmaceutical manufacturers to provide information into their oncology drugs in the pipeline in order for provinces to forecast their upcoming cancer drug submissions resource requirements to facilitate timely reviews. The 2019 survey continues to focus on information that should be available in the public domain but may be difficult to find in one source in a consistent manner.
  4. Proposal to Harmonize, Streamline and Transition the Cancer Drug Implementation Advisory Committee to CADTHCADTH is currently exploring new streamline processes with the Cancer Drug Implementation Advisory Committee (CDIAC) on how some of the implementation advisory functions can be transferred to CADTH.  The initial focus will be on cancer drugs, but may expand over time to include non-cancer drugs. As well, there has been no decisions regarding CADTH’s intention to adopt the committee as is.CADTH will be consulting with all key stakeholders in early 2019 throughout the transfer to ensure that the implementation advisory functions continue to meet stakeholder’s needs.

New updates from CDR are as follows:

  1. New Initiative: A Call for Clinical ExpertsFor all review processes for CDR submissions filed on or after January 2, 2019 CADTH will be issuing a Call for Clinical Experts. This new initiative aims to recruit clinical experts interested in working with CADTH and participating in the review process. Interested clinicians will be able to register by completing  a web form with contact information, areas of expertise and interests. A Call for Clinician Input will be issued at the same time as the Call for Patient Input currently posted.

    For more information, please visit the CADTH Website.

 pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update as of November 30th, 2018

The pCPA released its latest Negotiations Status Update on November 30, 2018. The following table summarizes the current status of pCPA negotiations and recent activity since October 31, 2018. For more information, please consult the pCPA website.

Negotiations Underway

 Negotiations Completed
with LOI		 Negotiations closed
without LOI

No Negotiations
New Since Last Update
  • Dupixent (dupilumab): Used to treat atopic dermatitis
  • Fasenra (benralizumab): Used to treat eosinophilic asthma
  • Januvia (sitagliptin): Used to treat type 2 diabetes mellitus
  • Kanuma (sebelipase alfa): Used to treat lysosomal acid lipase deficiency
  • Prevymis (letermovir): Used for the prevention of cytomegalovirus infection
  • Probuphine (buprenorphine): Used to treat of opioid use disorder
  • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol): Used to treat chronic obstructive pulmonary disease
  • Darzalex (daratumumab): Used to treat multiple myeloma
  • Ilaris (canakinumab): Used to treat systemic juvenile idiopathic arthritis
  • Jevtana (cabazitaxel): Used to treat castration resistant metastatic prostate cancer
  • MDK-Nitisinone (nitisinone): Used to treat hereditary tyrosinemia, type 1
  • Nitisinone (nitisinone): Used to treat hereditary tyrosinemia, type 1
  • Orfadin (nitisinone): Used to treat hereditary tyrosinemia, type 1
  • Taltz (ixekizumab):Used to treat psoriatic arthritis
  • Tecentriq (atezolizumab): Used to treat non-small cell lung cancer
  • Vimizim (elosulfase alfa): Used to treat mucopolysaccharidosis IVA (Morquio A syndrome)
  • Cinqair (reslizumab): Used to treat severe eosinophilic asthma
  • Copaxone (glatiramer acetate): Used to treat multiple sclerosis
  • Adempas (riociguat):Used to treat pulmonary arterial hypertension
  • Humira (adalimumab): Used to treat Hidradenitis suppurativa
  • Nucynta (tapentadol hydrochloride): Used to treat severe pain
  • Ozanex (ozenoxacin):Used to treat impetigo
  • Ozurdex (dexamethasone): Used to treat diabetic macular edema
  • Viberzi (eluxadoline): Used to treat irritable bowel syndrome
  • Xgeva (denosumab): Used to treat skeletal-related events due to bone metastases

Total

51 Negotiations 255 Joint Negotiations 30 Drug Negotiations 58 Drug Products

Coming in 2019, PDCI will be updating our look as we bring new insights and trends to our pCPA reviews. The new reviews will provide our readers with additional perspectives for building market access and pCPA negotiation strategies.

/ CADTH, pCPA, What's New